Clinical trials: Melphalan
Immune Deficiency Disorders, Severe Combined Immunodeficiency
Immune Disorder HSCT Protocol
This study hypothesizes that a reduced intensity immunosuppressive preparative regimen will establish engraftment of donor hematopoietic cells with acceptable early and delayed toxicity in patients with immune function disorders.
- Conditions
- Immune Deficiency Disorders, Severe Combined Immunodeficiency, Chronic Granulomatous Disease, X-linked Agammaglobulinemia
- Trial name
- NCT01821781
- Testing
- Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Washington University School of Medicine
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma
Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma
This phase II trial studies how well busulfan, melphalan, and bortezomib before first-line stem cell transplant works in treating patients with multiple myeloma.
- Conditions
- DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT01605032
- Testing
- Busulfan, Melphalan, Bortezomib
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Albert Einstein College of Medicine
Multiple Myeloma
HD Melphalan and SCT in Patients With IGDD or LCDD
RATIONALE: Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them.
- Trial name
- NCT00681044
- Testing
- filgrastim, melphalan, Stem Cell Infusion
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Boston Medical Center
Myeloma
Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients
Primary Objectives: 1. To evaluate the toxicity and safety of a combination of bortezomib with arsenic trioxide, ascorbic acid and high-dose melphalan in patients with multiple myeloma 2.
- Trial name
- NCT00469209
- Testing
- Trisenox (Arsenic Trioxide), Velcade (Bortezomib), Melphalan
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Myelodysplastic Syndrome
Combined Haploidentical-Cord Blood Transplantation for Adults and Children
The primary objective is to assess the rate of engraftment with combined haploidentical-cord blood transplantation. The secondary objective is to evaluate the incidence and severity of acute and chronic graft-versus-host disease…
- Conditions
- Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, Lymphoma
- Trial name
- NCT00943800
- Testing
- Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG), Stem Cell Transplant, Stem Cells Collections
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- University of Chicago
Multiple Myeloma
UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
The purpose of this study is to improve the clinical outcomes of research subjects with high-risk multiple myeloma in the context of the immediately preceding Total therapy 5 trial 2008-02 and Total therapy 3 trials 2003-33 and…
- Trial name
- NCT02128230
- Testing
- myPRS, Induction 1 - MEL-10+CFZ-TD-PACE, First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Arkansas
Testicular Cancer
High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors
The goal of this clinical research study is to learn if 2 cycles of high-dose chemotherapy can help to control germ-cell tumors.
- Trial name
- NCT00936936
- Testing
- Gemcitabine, Docetaxel, Melphalan
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
RATIONALE: Giving melphalan and bortezomib before and after a stem cell transplant stops the growth of abnormal cells by stopping them from dividing or killing them.
- Trial name
- NCT00790647
- Testing
- filgrastim, bortezomib, melphalan
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Boston Medical Center
Leukemia, Acute, Chronic Myelogenous Leukemia (CML)
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
Patients with hematologic malignancies will receive myeloablative chemotherapy followed by stem cell rescue with bone marrow or hematopoietic peripheral blood stem cells collected by apheresis from a filgrastim- (G-CSF)-mobilized…
- Conditions
- Leukemia, Acute, Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL)
- Trial name
- NCT01050764
- Testing
- Regulatory T-cells, Conventional T-cells, Melphalan
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Everett Meyer
Leukemia, Myelodysplastic Syndrome
Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor
The purpose of this research study is:(1) to determine if high doses of chemotherapy without total body irradiation can allow selected stem cells to take and grow,(2) to determine if selected stem cells from the blood or marrow…
- Conditions
- Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Allogeneic Marrow Transplant
- Trial name
- NCT00582933
- Testing
- BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma
This phase II trial studies the effectiveness of melphalan, peripheral stem cell transplantation, and interleukin-2 followed by interferon alfa in treating patients who have advanced multiple myeloma (MM).
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00006244
- Testing
- melphalan, recombinant interferon alfa, aldesleukin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Fred Hutchinson Cancer Center
Renal Impairment, Multiple Myeloma
PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function
This was a multicenter study of the pharmacokinetics (PK) of melphalan during treatment with melflufen and dexamethasone in patients with relapsed refractory multiple myeloma (RRMM) and impaired renal function.
- Trial name
- BRIDGE (NCT03639610)
- Testing
- Melflufen, Dexamethasone
- Where
- 10 sites in Czechia, Greece and 1 more
- Volunteers
- 35 people
- Sponsor
- Oncopeptides AB
Adrenoleukodystrophy, Metachromatic Leukodystrophy
HSCT for High Risk Inherited Inborn Errors
Hematopoietic stem cell transplantation has proven effective therapy for individuals with adrenoleukodystrophy (ALD), metachromatic leukodystrophy (MLD) or globoid cell leukodystrophy (GLD, or Krabbe disease).
- Conditions
- Adrenoleukodystrophy, Metachromatic Leukodystrophy, Globoid Cell Leukodystrophy, Tay Sachs Disease
- Trial name
- NCT00383448
- Testing
- Clofarabine, Total body Irradiation, Melphalan
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Myelofibrosis
Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis
Stem cell transplantation is used to treat may types of diseases. There a 2 types of transplants, conventional (very intense) and reduced intensity-non-myeloablative, also called mini-transplants.
- Trial name
- NCT00572897
- Testing
- Fludarabine, Melphalan +/- ATG
- Where
- 12 sites in United States, Canada and 2 more
- Volunteers
- 66 people
- Sponsor
- John Mascarenhas
Multiple Myeloma
Effects of Exercise in Combination With Epoetin Alfa
The purpose of the study was to determine the effect of Epoetin alfa therapy (short term versus long term) with and without a home-based individualized exercise program that incorporated aerobic and strength resistance training…
- Trial name
- NCT00577096
- Testing
- Epoetin Alfa, Exercise, Autologous Peripheral Blood Stem Cell Transplantation
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Arkansas
Light Chain Deposition Disease (LCDD or MIDD), Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD)
Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis
The goal of this clinical trial is to determine the toxicity and also the efficacy of a treatment that includes the following treatment: Two medications, bortezomib and dexamethasone (or BD), followed by autologous stem cell…
- Conditions
- Light Chain Deposition Disease (LCDD or MIDD), Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD), Monoclonal Immunoglobulin Deposition Disease (MIDD), Amyloidosis
- Trial name
- NCT01383759
- Testing
- Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
The purpose of this study is to evaluate the effectiveness of Bortezomib when added to standard chemotherapy medicine(s) for treatment of Multiple Myeloma.
- Trial name
- NCT00948922
- Testing
- Bortezomib, Melphalan, Autologous Stem Cell Transplant
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Multiple Myeloma
Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment
This study is designed to decrease toxicity associated with prior tandem transplant protocols by reducing the intensity of induction, consolidation and maintenance therapy, while increasing event-free survival by adding…
- Trial name
- NCT01548573
- Testing
- Dexamethasone, Tandem autologous stem cell transplant, Cisplatin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Iowa
Multiple Myeloma
Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma
This is a phase I clinical trial. Patients with a diagnosis of multiple myeloma undergoing autologous transplantation will receive a preparative regimen of melphalan, bendamustine, and carfilzomib.
- Trial name
- NCT02148913
- Testing
- Cohort 1: Carfilzomib 15 mg/m2, Cohort 2: Carfilzomib 20 mg/m2, Cohort 2b: Carfilzomib 20 mg/m2
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Corewell Health West